Smoking is the most significant cause of preventable deaths in England, and the health risks associated with smoking well documented. This not only puts a heavy burden on the healthcare system but also has a substantial social impact.
Its link to health inequalities is more evident because it is more prevalent amongst the most vulnerable in our society, with low educational attainment and poor socioeconomic status.
Even as smoking rates progressively reduced, these patients remained the most difficultto reach with cessation services.
Recent years have also seen many local authorities stop providing locally commissionedNHS stop smoking service, citing funding constraints. The postpandemic financial reckoning may yet see more strain on what is left in the coffers.
The Healthy Living pharmacy ethos community pharmacy teams, proactively supporting patients to quit and advising on the best evidence-shaped approach, deliver successful outcomes.
The Medicines and Healthcare products Regulatory Agency (MHRA) has advised the public to exercise caution when buying anti-choking devices online,
ensuring these products are purchased from reputable sellers.
As estimated by the regulator, more than 10,000 counterfeit or unbranded anti-choking devices have been purchased by the public within the last two years through
listings on online marketplaces such as Amazon and eBay, as well as drop-shipping websites.
People are cautioned that the use of such products poses a substantial risk of failure in clearing blockages and could exacerbate the situation by pushing
obstructions further down into the airway passage.
Dr Alison Cave, MHRA Chief Safety Officer, said: "Buying anti-choking devices that do not have a valid UKCA or CE mark increases the risk of receiving a product
which does not include appropriate instructions and is either fake or does not meet the UK's regulatory requirements.
"These products do not meet our strict quality standards and may put your health and safety at significant risk by failing to resolve or even worsening choking
incidents."
Community Pharmacies are set to significantly upgrade their digital security as the mandatory rollout of NHSmail Multi-Factor Authentication (MFA) begins
this month (August 1, 2024).
In an announcement by the Community Pharmacy England (CPE), pharmacies are urged to make the updates following a period of optional MFA implementations that began
in late 2023.
According to the new requirements, the mandatory update is crucial for protecting patient privacy and the integrity of their health records.
By adding an extra layer of security beyond the standard email address and password, MFA helps safeguard against unauthorised access.
This is especially vital in light of increasing cyber threats targeting healthcare systems.
Cyberattacks, including ransomware, can compromise patient records and disrupt care delivery, making robust security measures essential.
The introduction of MFA aims to curb these risks.
According to cybersecurity research, MFA can prevent up to 80 per cent data breaches and block over 99.9 per cent of compromised accounts.
Britain's GlaxoSmithKline will receive $1.25 billion (about £921 million) from Gilead Sciences as part of a settlement between its HIV medicines unit and the
US-based drugmaker, ending a long-drawn patent dispute.
The settlement, announced by GSK on Tuesday (February 1), relates to Gilead's antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which
GSK said in 2018 infringed on its unit ViiV Healthcare's dolutegravir and other similar compounds.
HIV medicines developed by ViiV, in which Pfizer and Japan's Shionogi also hold small stakes, are a major part of GSK's plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm.
The payment is expected to be made in the first quarter this year, London-listed GSK said. Gilead will also pay a 3 per cent royalty until 2027 on sales of Biktarvy and on future US sales of any product containing its main component.
The Independent Pharmacies Association (IPA), in collaboration with the Association of Optometrists (AOP), the British Dental Association (BDA) and the
NHS Confederation has written to health secretary Wes Streeting, urging him to ensure sustainable investment in primary care to strengthen the NHS and better
serve patients.
In their letter, the group congratulated Streeting on his recent appointment as Secretary of State for Health and Social Care and requested a meeting to provide
their joint constructive input towards improving health outcomes.
They expressed concern that recent administrations have failed to follow through on promises to properly integrate and fund primary care, leading to deteriorating
health outcomes.
"Our collective experience is that our National Health Service (NHS), and health outcomes generally, have suffered at the hands of recent administrations that have
talked much about the importance of properly integrating and funding primary care but not followed through with action," they wrote.
The associations emphasised the need to transition the NHS to a Neighbourhood Health Service, where more care is delivered within local communities to identify
problems earlier.
The final report of the Infected Blood Inquiry has been published today, bringing to light a devastating chapter in the history of the UK's healthcare system.
The inquiry, which was launched by former Prime Minister Theresa May in 2017, examined how contaminated blood products infected over 30,000 NHS patients with
deadly viruses, including HIV and Hepatitis C, between the 1970s and 1990s.
Following the publication of the report, Prime Minister Rishi Sunak issued a formal apology on behalf of successive governments, acknowledging the state's
significant failings.
He stated that he finds it "impossible to comprehend" how victims felt when injected with deadly diseases through no fault of their own.
The General Pharmaceutical Council (GPhC) has published a new strategy pledging to deliver equality, improve diversity and foster inclusion in all aspects of its work.
The strategy was updated after a public consultation held between April and July. It's key themes are:
To make regulatory decisions that are demonstrably fair, lawful, and free from discrimination and bias.
To use our standards to proactively help tackle discrimination and to make sure everyone can access person-centred care, fostering equality of health outcomes.To lead by example and demonstrate best practice within our organisation, holding ourselves to the same high standards we expect of others.
GPhC chair Nigel Clarke said having a strategy is vital as the pandemic has exposed "the scope and scale of inequities in society, in healthcare outcomes and in pharmacy."
"Inequality and exclusion are bad for people's health. Therefore, this strategy is fundamental to our core purpose as a regulator and our vision for safe and effective pharmacy care at the heart of healthier communities."
The Medicines and Healthcare Products Regulatory Agency (MHRA) is considering the reclassification of Aquiette 2.5mg tablets contains oxybutynin hydrochloride that is used to treat women with milder symptoms of overactive bladder from Prescription-Only-Medicine (POM) to Pharmacy (P) medicine.
The agency is encouraging pharmacists, GPs and other health care professionals, the public and women to take part in the reclassification consultation to make a
treatment for overactive bladder available for women without the need for a prescription.
Public consultation on a set of proposals to make Aquiette 2.5mg Tablets (oxybutynin hydrochloride) available from pharmacies will close on 13 May, 2022.
It would be the first time a medicine for the treatment of overactive bladder would be available without prescription, if the reclassification consultation receives positive responses.
After the decision is made to reclassify this treatment, pharmacists will have access to training materials and a checklist to enable them to identify women who can be supplied this medicine safely.
The Department of Health and Social Care (DHSC) and NHS England last month issued a "safety critical" national patient safety alert, warning about
the UK-wide shortage of a life-saving drug used to treat patients with chronic breathing issues.
NHS trusts, health authorities, ambulance services, GP practices, private healthcare providers, and community pharmacy contractors were informed that
salbutamol 2.5mg and 5mg nebuliser liquid unit dose vials are in short supply, with the latter likely to remain "out of stock" until mid-April 2024.
As per the alert, the shortage of the drug resulted from a combination of manufacturing issues, leading to heightened demand for alternative suppliers.
It was mentioned that while terbutaline, salbutamol with ipratropium, and ipratropium nebuliser liquids remained available, they could't meet the increased demand.
Most people in Great Britain believe that new junior doctors, nurses and health care assistants are underpaid, senior doctors and matrons are paid about right,
and NHS CEOs are paid too much, according to a new study.
About half the people surveyed indicated that newly qualified junior doctors are paid too little, with this sentiment increasing to three in five (60 per cent) among
Labour voters.
The research conducted by the Policy Institute at King's College London, King's Business School, and Ipsos also showed that more people believe NHS staff overall were
badly paid than well paid.
Dr Nick Krachler, senior lecturer in Human Resource Management at King's Business School, said: "Our survey shows considerable alignment between public perception
of NHS pay levels and the claims of trade unions and professional associations that pay levels - which are determined by government after consultation from a Pay
Review Body - are unsatisfactory for frontline NHS roles."
He highlighted the urgent need to address healthcare workers' economic wellbeing, hoping that the new government will consider it in its upcoming negotiations with
junior doctors this week.
Southwark Crown Court on Thursday sentenced two pharmacists to two years of imprisonment each, suspended for 24 months, after they were found guilty of
selling 'industrial' quantities of Class C controlled drugs.
Mandip Sidhu (47) of Littleover, Derby and Nabeil Nasr (42) of Cheadle, Greater Manchester, pleaded guilty at an earlier hearing following an investigation by
the Criminal Enforcement Unit of the Medicines and Healthcare Products Regulatory Authority (MHRA).
Both Sidhu and Nasr were pharmacists registered with the General Pharmaceutical Council at the time of the offenses, which took place between May 2013 and
June 2017. Sidhu was the director of Pharmaceutical Health Limited (PHL) in Derby, while Nasr owned several pharmacies across the North West of England.
Sidhu was sentenced to two years imprisonment on each of five counts of supplying Class C drugs and four months for forgery, all to run concurrently and suspended
for 24 months. Additionally, she must complete 200 hours of community service for her role in the illegal supply of diazepam, zolpidem, and zopiclone.
More pharmacies should do NHS Health Checks to improve access, a new study that focuses on ways to improve the lives of people living with obesity, recommends.
The report, Levelling Up Obesity Care, by pharma giant Novo Nordisk follows a series of roundtables with patient advocates, healthcare professionals and academics to generate understanding on the future of obesity care in England.
Amongst its recommendations, the report says that 'to widen access and alleviate pressure on GP services, consideration should be given to expanding NHS Health
Checks in community pharmacy'.
NHS Health Checks include a measurement of Body Mass Index (BMI).
Those most likely to benefit from a Health Check include people who live in more deprived areas, and are more likely to be living with obesity, says the report.
The Medicines & Healthcare products Regulatory Agency has initiated a recall of three batches of Quantum Pharmaceutical's Diltiazem HCl 2% Cream, which is an
unlicensed medicine. MHRA issued a precautionary recall of the cream due to a change in the product's appearance that affected its thickness.
Pharmacists are instructed to halt supply, quarantine remaining stock, and contact Quantum Pharmaceutical to return affected batches M1402497, M1402574, and M1402680.
Patients using this product may encounter application issues with the cream due to its consistency. However, MHRA said that this has not impacted the product's
effectiveness or posed any risk to patient safety.
The MHRA also reported that medac GmbH (t/a medac Pharma LLP) is conducting a recall of two batches of Sodiofolin 50 mg/ml solution for injection/infusion
(400mg/8ml vial) with batch numbers G220393B and G220393C. This class 2 medicines recall is a result of particles detected during long-term stability tests.
Rowlands pharmacy has launched a new weight management service across its UK network, challenging perceptions around weight loss and providing expert support
to those in need.
The launch comprises a pilot roll-out across 100 Rowlands branches to increase consideration of pharmacies for weight management-based advice.
Commenting on the launch, Nigel Swift, managing director of Rowlands, said: "One of the biggest challenges facing many adults looking to address any weight concerns
is knowing where and how to start. Our new weight management service is designed to help all those setting out on a new weight loss journey but also those who have
struggled to find a plan that works for them."
"Our pharmacy teams offer comprehensive healthcare advice and a variety of weight management products with a friendly approach that naturally puts customers at ease,
and we're looking forward to welcoming all those looking to take their first step with us."
AAH Pharmaceuticals (AAH) has announced the appointment of Brain Chambers as Chief Commercial Officer.
"I'm proud to lead the commercial functions in AAH in my new role and broader area of responsibility." Said Brian. "I'm committed to delivering on great value for
our customers and building and strengthening our supplier partnerships."
Brain is associated with AAH Pharmaceuticals for more than 14 years. He joined the organisation as Business Development Manager in October 2008. His previous role
in the organisation was on Sales and Marketing Director.
He posted on LinkedIn: "This is a big move for me personally, but that's a side hustle. What is the main play here is AAH becoming a standalone independent wholesale
business focussed on only the AAH customer and our core business and this is just one part of that.
In response to new research that revealed inequality in menopause support with 51 per cent of women from black, Asian and minority ethnic backgrounds,
Holland & Barrett, the UK's leading health and wellness retailer, has decided to continue its menopause campaign work to make "every menopause matter".
A quarter of women (26 per cent) from minority ethnic communities say they find it difficult to access menopause support relevant to their specific backgrounds.
Alongside support from Olympian and menopause campaigner, Michelle Griffith Robinson and expert, Meera Bhogal, the retailer is launching several new initiatives
to make its information and support on menopause more inclusive by offering more diverse and personalised advice and content, tailored to different needs.
Almost a third (31 per cent) believe being able to speak to a female healthcare professional of the same ethnicity as them would have made a difference to their
menopause experience. Fifteen per cent go as far as saying that communicating in their native language would have made a positive difference.
Based on these findings, Holland and Barrett is the first retailer to launch a free, multi-language menopause online consultation service. The service will
see trained H&B menopause advisors offering guidance and symptom support in multiple languages, starting with Hindi, Urdu, Gujarati and Punjabi.
The Royal Pharmaceutical Society (RPS) has said that multi-buy deals on paracetamol violate the existing voluntary sales guidelines.
The professional body is urging the government to pass legislation that prohibits retailers from making such offers on medicines for pain relief.
They have also sent letters to MP Maria Caulfield who is the Minister for Mental Health and Women's Health.
The Medicines and Healthcare Products Regulatory Agency (MHRA) is requesting to take action on the legislation at the earliest.
The concern raised is that multi-buy offers such as 'buy one get one free' can encourage people to buy and store excess packs, which may lead to accidental
or impulsive overdose.
The government has earmarked £200 million to enhance NHS resilience and expedite patient care during the upcoming winter season. This extra amount will
bolster the health service during its busiest period, while protecting elective care so we can keep cutting waiting lists, Prime Minister Rishi Sunak has said.
On August 13, the Prime Minister and Health and Social Care Secretary met with clinical leaders and NHS Chiefs to strategise and refine planning for urgent and
emergency care, while prioritising the preservation of waiting list targets for the upcoming winter season.
"Patients can be reassured that I will always back the NHS, so that those who most need help and support will get the care they need," Sunak said. "Winter is
the most challenging time for the health service, which is why we've been planning for it all year - with huge government investment to fund new ambulances, beds
and virtual wards."
"This £200 million investment, assured by the Department of Health and Social Care as new and additional funding, should aid NHS leaders in their preparations and
mitigation for what will be a seriously difficult winter period," said Matthew Taylor, Chief Executive of NHS Confederation. "The priority now is swift allocation
of funding to local systems for optimal utilisation."
NHS England and NHS Improvement (NHSE&I), in association with the Royal Pharmaceutical Society (RPS) and the Association of Pharmacy Technicians UK (APTUK),
has published its first inclusive pharmacy practice (IPP) bulletin, with an overarching ambition "to make community pharmacy a more inclusive environment for all
pharmacy professionals".
The IPP programme will take practical steps to improve the awareness and understanding at all levels of different cultural beliefs and attitudes, according to the
Pharmaceutical Services Negotiating Committee (PSNC).
As a member of the IPP Improving Practice and Engagement Group, PSNC has contributed to this issue of the Bulletin, which focuses on how pharmacy professionals can
help to reduce health inequalities via the detection and prevention of cardiovascular diseases.
The IPP programme, of which the Bulletin forms a part, aims to engage with local communities to help improve their health and reduce inequalities in care -
particularly among those from ethnically diverse and disadvantaged backgrounds.